RPS27P29: A Promising Drug Target / Biomarker (G100132291)

Target Name: RPS27P29

NCBI ID: G100132291

RPS27P29

Other Name(s): RPS27_17_1641 | ribosomal protein S27 pseudogene 29 | Ribosomal protein S27 pseudogene 29

RPS27P29: A Promising Drug Target / Biomarker

The protein RPS27P29 is a key regulator of the actinin-based cytoskeleton, which is a complex network of filaments that provides structural support to eukaryotic cells. RPS27P29 is a 29-kDa protein that is expressed in a variety of tissues and cells, including muscle, nerve, and epithelial cells. It is involved in the regulation of cell shape, cytoskeleton dynamics, and actinin-based cytoskeleton organization.

Drug Targeting

RPS27P29 is a drug target of interest in the field of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the formation of neurofibrillary tangles, which are thought to contribute to the degenerative changes observed in these conditions.

One of the mechanisms by which RPS27P29 is thought to contribute to neurodegenerative disease is its role in the regulation of the actinin-based cytoskeleton. The actinin-based cytoskeleton provides structural support to the brain and is involved in many critical cellular processes, including cell migration, invasiveness, and mechanical forces. The misregulation of actinin-based cytoskeleton organization has been implicated in the development and progression of neurodegenerative diseases.

In addition to its role in the actinin-based cytoskeleton, RPS27P29 is also involved in the regulation of cell shape and the maintenance of cell viability. It is part of a complex that regulates the formation and stability of the actinin-based cytoskeleton, and is thought to play a key role in the regulation of cell shape and the ability of cells to survive and grow in various environments.

Biomarker

The availability of reliable biomarkers for the diagnosis and treatment of neurodegenerative diseases is a major goal in the field of neuroscience. RPS27P29 is a potential biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The regulation of actinin-based cytoskeleton organization is thought to be abnormal in these conditions, and the misregulation of actinin-based cytoskeleton organization has been implicated in the development and progression of these diseases.

In addition to its potential as a drug target, RPS27P29 is also a potential biomarker for neurodegenerative diseases. The regulation of cell shape and the maintenance of cell viability is thought to be abnormal in these conditions, and the misregulation of actinin-based cytoskeleton organization has been implicated in the development and progression of these diseases. Therefore, RPS27P29 may be a useful biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

In conclusion, RPS27P29 is a protein that is involved in the regulation of actinin-based cytoskeleton organization and is expressed in a variety of tissues and cells. It is a potential drug target and biomarker for the diagnosis and treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Further research is needed to fully understand the role of RPS27P29 in these conditions and to develop effective treatments.

Protein Name: Ribosomal Protein S27 Pseudogene 29

The "RPS27P29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS27P29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets